allocholic acid: see also records for ursocholic and cholic acids [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
allocholic acid : An allo-bile acid that is 5alpha-cholan-24-oic acid bearing three alpha-hydroxy substituents at position 3, 7 and 12. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
ID Source | ID |
---|---|
PubMed CID | 160636 |
CHEBI ID | 81308 |
SCHEMBL ID | 288659 |
MeSH ID | M0042451 |
Synonym |
---|
5a-cholic acid |
LMST04010092 |
3alpha,7alpha,12alpha-trihydroxy-5alpha-cholan-24-oic acid |
allocholic acid |
3alpha,7alpha,12alpha-trihydroxy-5alpha-cholanoic acid |
C17737 |
2464-18-8 |
(4r)-4-[(3r,5r,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoic acid |
cholan-24-oic acid, 3,7,12-trihydroxy-, (3alpha,5alpha,7alpha,12alpha)- |
SCHEMBL288659 |
5alpha-cholic acid |
CHEBI:81308 |
(3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxycholan-24-oic acid |
3a,7a,12a-trihydroxy-5a-cholanoic acid |
AC-33240 |
mfcd28359001 |
3,7,12-trihydroxy-(3alpha,5alpha,7alpha,12alpha)-cholan-24-oate |
3a,7a,12a-trihydroxy-5a-cholan-24-oic acid |
5a-cholate |
3a,7a,12a-trihydroxy-(5a)-cholan-24-oate |
5a-allocholate |
3a,7a,12a-trihydroxy-5a-cholan-24-oate |
5a-allocholic acid |
3,7,12-trihydroxy-(3alpha,5alpha,7alpha,12alpha)-cholan-24-oic acid |
3a,7a,12a-trihydroxy-(5a)-cholan-24-oic acid |
AKOS032949627 |
CS-0103175 |
HY-125934 |
Q27155245 |
DTXSID60859117 |
5alpha-allocholic acid |
MS-27027 |
3-alpha,7-alpha,12-alpha-trihydroxy-5-alpha-cholanoic acid |
CAA87663 |
Role | Description |
---|---|
marine metabolite | Any metabolite produced during a metabolic reaction in marine macro- and microorganisms. |
rat metabolite | Any mammalian metabolite produced during a metabolic reaction in rat (Rattus norvegicus). |
human metabolite | Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens). |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
C24-steroid | A steroid compound with a structure based on a 24-carbon (cholane) skeleton. |
3alpha-hydroxy steroid | A 3-hydroxy steroid in which the 3-hydroxy substituent is in the alpha-position. |
7alpha-hydroxy steroid | A 7-hydroxy steroid in which the hydroxy group at position 7 has an alpha-configuration. |
12alpha-hydroxy steroid | |
allo-bile acid | Any member of the class of bile acids having 5alpha-configuration. Usually found in lower vertebrates. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 5 (55.56) | 18.7374 |
1990's | 1 (11.11) | 18.2507 |
2000's | 1 (11.11) | 29.6817 |
2010's | 2 (22.22) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.86) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (11.11%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (88.89%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |